Papers - TOKUDA Emi
-
【エストロゲン受容体陽性転移乳癌の薬物療法】CDK4/6阻害薬
徳田 恵美, 佐治 重衡
日本内分泌外科学会誌 36 ( 2 ) 101 - 106 2019.6
-
Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
Horimoto Y, Tokuda E, Murakami F, Uomori T, Himuro T, Nakai K, Orihata G, Iijima K, Togo S, Shimizu H, Saito M.
J Transl Med. 16 ( 1 ) 287 2018.10
-
Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital
Yoshida-Ichikawa Y, Tanabe M, Tokuda E, Shimizu H, Horimoto Y, Miura K, Saito M.
Case Rep Oncol. 11 ( 2 ) 511 - 520 2018.7
-
Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer.
Okazaki M, Horimoto Y, Tanabe M, Ichikawa Y, Tokuda E, Arakawa A, Kobayashi T, Saito M.
Med Oncol. 35 ( 4 ) 48 2018.3
-
CDK6 might be a key factor for efficacy of CDK4/6 inhibitor and the hormone sensitivity following acquired resistance
Iida Masafumi, Nakamura Misato, Tokuda Emi, Niwa Toshifumi, Ishida Takanori, Hayashi Shin-ichi
CANCER RESEARCH 78 ( 4 ) 2018.2（ ISSN:0008-5472 ）
-
Effects of PI3K inhibitors on endocrine-resistant cell lines and differences in the characteristics of ER positive breast cancer cells after acquired resistance to the inhibitors
Tokuda Emi, Komatsu Takayuki, Sasaki Shunta, Tsuboi Kouki, Nakamura Misato, Iida Masafumi, Niwa Toshifumi, Saito Mitsue, Hayashi Shin-Ichi
CANCER RESEARCH 78 ( 4 ) 2018.2（ ISSN:0008-5472 ）
-
MESENCHYMAL CIRCULATING TUMOUR CELL ANALYSIS TO PREDICT EFFICACY OF ERIBULIN FOR METASTATIC BREAST CANCER PATIENTS
Yoshiya Horimoto, Emi Tokuda, Fumi Murakami, Katsuya Nakai, Hideo Shimizu, Mitsue Saito
BREAST 36 S40 - S41 2017.11（ ISSN:0960-9776 ）
-
Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer.
Tokuda E, Horimoto Y, Arakawa A, Himuro T, Senuma K, Nakai K, Saito M.
Hum Pathol. 63 40 - 45 2017.5
-
【乳癌学-最新の診断と治療-】 乳癌の分子生物学と発症機序 乳癌のサブタイプ 分子機構と薬物療法概論 エストロゲン依存性乳癌の分子機構と内分泌療法
林 慎一, 徳田 恵美
日本臨床 75 ( 増刊3 ) 112 - 117 2017.4（ ISSN:0047-1852 ）
-
ホルモン療法の感受性マーカー
徳田 恵美, 林 慎一
がん分子標的治療 15 ( 1 ) 66 - 71 2017.3（ ISSN:1347-6955 ）
-
Tumor marking for breast-conserving surgery of non-palpable early breast cancer presenting microcalcifications
M. Mori, E. Tokuda, Y. Horimoto, T. Uomori, F. Murakami, M. Tanabe, A. Shiraishi, A. Arakawa, K. Iijima, M. Saito
BREAST 32 S119 - S119 2017.3（ ISSN:0960-9776 ）
-
Activated Caspase 3 Expression in Remnant Disease After Neoadjuvant Chemotherapy May Predict Outcomes of Breast Cancer Patients.
Himuro T, Horimoto Y, Arakawa A, Matsuoka J, Tokuda E, Tanabe M, Saito M.
Ann Surg Oncol. 23 ( 7 ) 2235 - 2241 2016.7
-
Caspase 3 expression in remnant disease after neo-adjuvant chemotherapy may predict outcomes of breast cancer patients
T. Himuro, Y. Horimoto, A. Arakawa, E. Tokuda, M. Tanabe
EUROPEAN JOURNAL OF CANCER 57 S43 - S43 2016.4（ ISSN:0959-8049 ）
-
Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients.
Horimoto Y, Arakawa A, Tanabe M, Kuroda K, Matsuoka J, Igari F, Himuro T, Yoshida Y, Tokuda E, Shimizu H, Hino O, Saito M
J Clin Pathol. 68 ( 10 ) 825 - 829 2015.10
-
乳癌における上皮間葉転換 治療標的としての臨床応用の可能性
猪狩 史江, 堀本 義哉, 吉田 悠子, 徳田 恵美, 清水 秀穂, 田辺 真彦, 齊藤 光江
乳癌の臨床 30 ( 3 ) 229 - 236 2015.6（ ISSN:0911-2251 ）
-
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients.
Shimizu H, Horimoto Y, Arakawa A, Sonoue H, Kurata M, Kosaka T, Nakai K, Himuro T, Tokuda E, Takahashi Y, Taira F, Ito M, Abe I, Senuma K, Stork-Sloots L, de Snoo F, Saito M
Mol Clin Oncol 10 ( 2 ) 118 - 122 2015.4
-
Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases,
Horimoto Y, Arakawa A, Harada-Shoji N, Sonoue H, Yoshida Y, Himuro T, Igari F, Tokuda E, Mamat O, Tanabe M, Hino O, Saito M
Br J Cancer, 112 ( 2 ) 345 - 351 2015.1
-
Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer.
Horimoto Y, Arakawa A, Tanabe M, Sonoue H, Igari F, Senuma K, Tokuda E, Shimizu H, Kosaka T, Saito M.
BMC Cancer. 14 550 2014.7
-
【腹部救急疾患に対する内視鏡外科手術】 医原性大腸穿孔に対する腹腔鏡下手術
吉川 征一郎, 福永 正氣, 李 慶文, 永仮 邦彦, 菅野 雅彦, 須田 健, 飯田 義人, 伊藤 嘉智, 大内 昌和, 勝野 剛太郎, 徳田 恵美, 平崎 憲範, 呉 一眞, 東 大輔
日本腹部救急医学会雑誌 33 ( 1 ) 55 - 59 2013.1（ ISSN:1340-2242 ）
-
Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
Tokuda E, Seino Y, Arakawa A, Saito M, Kasumi F, Hayashi S, Yamaguchi Y.
Breast Cancer Res Treat. 133 ( 2 ) 427 - 436 2012.6